The inhibitory effects of ZBED6‐KO on obesity and muscle atrophy may also mitigate the muscle atrophy induced by existing drugs used for the treatment of obesity, providing potential insights for the development of novel therapeutic targets for obesity and diabetes. Here, ZBED6 is linked to diabetes mellitus.